181 related articles for article (PubMed ID: 36428999)
21. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
22. Tumor-stage mycosis fungoides in palmoplantar localization with large-cell transformation and partial CD30 expression shows complete response to brentuximab vedotin.
Pham AK; Carter JB; Ratcliffe NR; Fuld AD; Lansigan F; Burnside NJ; Guill MA; Zug KA; Jarvis LA; LeBlanc RE
J Cutan Pathol; 2018 Jun; 45(6):458-462. PubMed ID: 29512830
[TBL] [Abstract][Full Text] [Related]
23. Transformed mycosis fungoides: clinicopathological features and outcome.
Barberio E; Thomas L; Skowron F; Balme B; Dalle S
Br J Dermatol; 2007 Aug; 157(2):284-9. PubMed ID: 17573879
[TBL] [Abstract][Full Text] [Related]
24. [Mycosis fungoides in children and adolescents: a report of six cases with predominantly hypopigmentation, along with a literature review].
Rizzo FA; Vilar EG; Pantaleão L; Fonseca EC; Magrin PF; Henrique-Xavier M; Rochael MC
Dermatol Online J; 2012 Mar; 18(3):5. PubMed ID: 22483516
[TBL] [Abstract][Full Text] [Related]
25. Double-positive CD4/CD8 mycosis fungoides: a rarely reported immunohistochemical profile.
Tournier E; Laurent C; Thomas M; Meyer N; Viraben R; Brousset P; Lamant L
J Cutan Pathol; 2014 Jan; 41(1):58-62. PubMed ID: 24134789
[TBL] [Abstract][Full Text] [Related]
26. The expression of CXCR3 and CD30 in mycosis fungoides.
Nikoo A
Arch Iran Med; 2012 Mar; 15(3):146-50. PubMed ID: 22369302
[TBL] [Abstract][Full Text] [Related]
27. Role of B-cells in Mycosis Fungoides.
Nielsen PR; Eriksen JO; Sørensen MD; Wehkamp U; Lindahl LM; Bzorek M; Iversen L; Woetman A; Ødum N; Litman T; Gjerdrum LMR
Acta Derm Venereol; 2021 Mar; 101(3):adv00413. PubMed ID: 33686443
[TBL] [Abstract][Full Text] [Related]
28. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
29. Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation.
Raghavan SS; Hong EK; Kim YH; Kim J
J Cutan Pathol; 2019 Jan; 46(1):33-43. PubMed ID: 30328119
[TBL] [Abstract][Full Text] [Related]
30. Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors.
Pulitzer M; Myskowski PL; Horwitz SM; Querfeld C; Connolly B; Li J; Murali R
Pathology; 2014 Dec; 46(7):610-6. PubMed ID: 25393251
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in 105 Japanese cases of mycosis fungoides and Sézary syndrome: clusterin expression as a novel prognostic factor.
Tobisawa S; Honma M; Ishida-Yamamoto A; Saijo Y; Iizuka H
J Dermatol Sci; 2013 Sep; 71(3):160-6. PubMed ID: 23702390
[TBL] [Abstract][Full Text] [Related]
32. High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides.
de Masson A; O'Malley JT; Elco CP; Garcia SS; Divito SJ; Lowry EL; Tawa M; Fisher DC; Devlin PM; Teague JE; Leboeuf NR; Kirsch IR; Robins H; Clark RA; Kupper TS
Sci Transl Med; 2018 May; 10(440):. PubMed ID: 29743350
[TBL] [Abstract][Full Text] [Related]
33. The Microenvironment's Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications.
Pileri A; Guglielmo A; Grandi V; Violetti SA; Fanoni D; Fava P; Agostinelli C; Berti E; Quaglino P; Pimpinelli N
Cells; 2021 Oct; 10(10):. PubMed ID: 34685762
[TBL] [Abstract][Full Text] [Related]
34. Tumor-infiltrating and circulating granulocytic myeloid-derived suppressor cells correlate with disease activity and adverse clinical outcomes in mycosis fungoides.
Argyropoulos KV; Pulitzer M; Perez S; Korkolopoulou P; Angelopoulou M; Baxevanis C; Palomba ML; Siakantaris M
Clin Transl Oncol; 2020 Jul; 22(7):1059-1066. PubMed ID: 31696413
[TBL] [Abstract][Full Text] [Related]
35. Papular mycosis fungoides: a new clinical variant of early mycosis fungoides.
Kodama K; Fink-Puches R; Massone C; Kerl H; Cerroni L
J Am Acad Dermatol; 2005 Apr; 52(4):694-8. PubMed ID: 15793526
[TBL] [Abstract][Full Text] [Related]
36. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
[TBL] [Abstract][Full Text] [Related]
37. Adult pityriasis lichenoides-like mycosis fungoides: a clinical variant of mycosis fungoides.
de Unamuno Bustos B; Ferriols AP; Sánchez RB; Rabasco AG; Vela CG; Piris MA; Alegre de Míquel V
Int J Dermatol; 2014 Nov; 53(11):1331-8. PubMed ID: 24961281
[TBL] [Abstract][Full Text] [Related]
38. Progression of mycosis fungoides occurs through divergence of tumor immunophenotype by differential expression of HLA-DR.
Murray D; McMurray JL; Eldershaw S; Pearce H; Davies N; Scarisbrick JJ; Moss P
Blood Adv; 2019 Feb; 3(4):519-530. PubMed ID: 30770361
[TBL] [Abstract][Full Text] [Related]
39. Single-Cell RNA Sequencing Reveals Tissue Compartment-Specific Plasticity of Mycosis Fungoides Tumor Cells.
Rindler K; Bauer WM; Jonak C; Wielscher M; Shaw LE; Rojahn TB; Thaler FM; Porkert S; Simonitsch-Klupp I; Weninger W; Mayerhoefer ME; Farlik M; Brunner PM
Front Immunol; 2021; 12():666935. PubMed ID: 33968070
[TBL] [Abstract][Full Text] [Related]
40. Mycosis fungoides with CD30-positive cells in the epidermis.
Wu H; Telang GH; Lessin SR; Vonderheid EC
Am J Dermatopathol; 2000 Jun; 22(3):212-6. PubMed ID: 10871063
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
